


Attorney Docket No.: 5700.250-US

PATENT



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Jeppesen et al.

Application No.: 09/995,137

Group Art Unit: 1624

Filed: November 27, 2001

Examiner: Truong, Tamthom Ngo

For: Tricyclic Compounds as Nuclear Receptor Modulators

**SUPPLEMENTAL RESPONSE**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This supplemental response is submitted following the timely response dated April 21, 2003 to the non-final Office Action on the merits mailed January 21, 2003, having a shortened statutory period for reply set to expire April 21, 2003, subject to extensions of time under the provisions of 37 CFR §1.136(a).

**RESPONSE**

The Examiner noted that the oath/declaration filed concurrently with the application and preliminary amendment did not specifically refer to the preliminary amendment as required by 37 C.F.R. §1.63(b)(2). Applicant has enclosed a newly executed oath/declaration correcting the deficiency.

In the event that an extension of time is required for timely filing of the enclosed declaration, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

**RECEIVED**

JUN 13 2003

TECH CENTER 1600/2900

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this supplemental response. Applicant respectfully requests that a timely Notice of Allowance be issued in this case.

Respectfully submitted,



Date: June 2, 2003

Rosemarie R. Wilk-Orescan  
Registration Number 45, 220  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5969



23650

PATENT TRADEMARK OFFICE